Paramita Therapeutics Inc reported on Wednesday the receipt of a National Science Foundation Small Business Innovation Research grant valued at USD255,990 to conduct research and development work on a novel dual-function therapeutic/vaccine product, TheraVax, to help combat COVID-19.
According to Paramita, TheraVax can not only can block entry of SARS-CoV-2 but also can activate the immune system to produce effector T cells and neutralising antibodies to eliminate SARS-CoV-2. It's thought that this unique dual-function therapeutic/vaccine could work at an early stage of infection to prevent hospitalisation and in mild or severe disease to block viral spread while activating appropriate immune responses.
Following the award of the Phase I grant, the company is eligible to apply for a Phase II grant of up to USD1m. Small businesses with Phase II funding are eligible to receive up to USD500,000 in additional matching funds with qualifying third-party investment or sales.
Paramita is an early-stage specialty biotech company focused on developing new therapeutics for cancer and infectious diseases.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer